# EDGAR Filing Document

**Accession Number:** 0001834645
**File Stem:** 0001193125-23-039269
**Filing Date:** 2023-2
**Character Count:** 5285
**Document Hash:** 56c0bf2bc2b736ab2ffe91ecc8015eeb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-039269.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001193125-23-039269

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Peak Bio, Inc.
- **CENTRAL INDEX KEY:** 0001834645
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 852448157
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 3350 W BAYSHORE RD. SUITE 100
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94303
- **BUSINESS PHONE:** (650) 549-9103

**MAIL ADDRESS:**
- **STREET 1:** 3350 W BAYSHORE RD. SUITE 100
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94303

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ignyte Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201202

**Peak Bio, Inc.** 

3350 W. Bayshore Rd., Suite 100

Palo Alto, CA 94303

February 14, 2023

**VIA EDGAR** 

Attention: Jimmy McNamara <br> Suzanne Hayes

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Peak Bio, Inc.** |
|  | **Amendment No. 2 to Registration Statement on Form S-1** |
|  | **Filed February 1, 2023** |
|  | **File No. 333-268801** |

---

Ladies and Gentlemen:

This letter sets forth the response of Peak Bio, Inc. (the "***Company***" or "***Peak Bio***") to the comments of the staff of the Division of Corporation Finance (the "***Staff***") of the Securities and Exchange Commission set forth in your letter dated February 6, 2023 (the "***Comment Letter***"), with respect to the above referenced Amendment No. 2 to Registration Statement on Form S-1 (the "***Registration Statement***"). Concurrently with the submission of this letter, the Company is filing Amendment No. 3 to the Registration Statement (the "***Amended Registration Statement***"). In addition to addressing the comments raised by the Staff in the Comment Letter, the Company has included other revisions and updates to its disclosure in the Amended Registration Statement. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Amended Registration Statement.

Set forth below is the Company's response to the Staff's comments. For the Staff's convenience, we have incorporated your comments into this response letter in italics.

<u>Amendment No. 2 to Registration Statement on Form S-1</u> 

<u>Cover Page</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *We note your response to comment three and note that your shares are not currently listed on a national securities exchange or quoted on the OTC Bulletin Board, OTCQX or OTCQB. Therefore, the fixed price at which your selling shareholders can sell their shares pursuant to this registration statement must be disclosed in the registration statement. These shareholders can sell their shares* 

------

 *at the market price if the shares are listed on a national securities exchange or are quoted on the OTC Bulletin Board, OTCQX or OTCQB. Please revise your registration statement to disclose this selling price. Please note that if your selling shareholders sell their shares at negotiated prices, they are not relying on the registration statement, please remove the disclosure related to private transactions. Additionally, please explain why White Lion is only able to sell its shares of your Common Stock if it is listed on the Nasdaq Capital Market, the Nasdaq Global Select Market, the Nasdaq Global Market, the New York Stock Exchange or the NYSE American.*

**Response**: The Company respectfully acknowledges the Staff's comment and has revised its disclosure on the prospectus cover page and pages 7, 185, 195, 198 and 200 of the Amended Registration Statement in response.

<u>Recent Developments, page 98</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *We note your response to comment three and your disclosure indicating that Nasdaq intends to file a Form 25-NSE Notification of Delisting once all applicable appeal and review periods have expired. Please revise to clarify when the applicable appeal and review periods are schedule to expire and whether you intend to appeal the determination.* 

**Response**: The Company respectfully acknowledges the Staff's comment and has revised its disclosure on pages 8, 66 and F-91 of the Amended Registration Statement in response.

\*\*\*\*\*

------

We respectfully request the Staff's assistance in completing the review of the Amended Registration Statement as soon as possible. Please contact Andrew P. Gilbert of DLA Piper LLP (US) at (973) 520-2553 or Scott A. Cowan of DLP Piper LLP (US) at (973) 520-2554 with any questions or further comments regarding the responses to the Staff's comments.

---

| | |
|:---|:---|
|  Sincerely, | Sincerely, |
|  PEAK BIO, INC. | PEAK BIO, INC. |
| By: | /s/ Stephen LaMond |
|  | Name: Stephen LaMond |
|  | Title: Interim Chief Executive Officer |

---

cc: Stephen LaMond, Peak Bio, Inc.

Andrew P. Gilbert, DLA Piper LLP (US)

Scott A. Cowan, DLA Piper LLP (US)